Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | XBP1 | P17861 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 11/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.56 |
| ▸ | TUBB | P07437 | 1/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077176 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL8689527 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL829961 | 0.86 | ALDH1A1 (0.71) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL8795558 | 0.85 | ALOX15 (0.68) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL18531909 | 0.85 | GAA (0.63) | ALDH1A1HPGDGAAMAPTSMN1; SMN2 | |
| SCHEMBL6308065 | 0.85 | KDM4E (0.58) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL2204971 | 0.84 | KMT2A (0.56) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL4317810 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL12496609 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL1503892 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614229-B2 | Substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2419408-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-5852046-A | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | IDO1, TPH1, AHR | ALDH1A1 2066/4885HPGD 719/4885CYP1A2 101/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | ALDH1A1 3430/4885HPGD 1610/4885CYP1A2 3257/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | ALDH1A1 3319/4885HPGD 2022/4885CYP1A2 2631/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | ALDH1A1 3319/4885HPGD 2022/4885CYP1A2 2631/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | ALDH1A1 3319/4885HPGD 2022/4885CYP1A2 2631/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | ALDH1A1 3319/4885HPGD 2022/4885CYP1A2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.